2027 – Call For Abstracts – Paris

By submitting an abstract, you confirm the following:

• You agree to present the abstract if it is selected for presentation. This includes being present during the scheduled time of a poster session.
• You verify that your clinical research was approved by an appropriate ethics committee or institutional review board (IRB), and, where applicable, that informed consent was obtained from all human subjects.
• You assign copyright of the abstract to the Keloid Research Foundation (unless you are a U.S. federal employee).
• All authors and contributors agree to comply with the KRF Confidentiality Policy.

Indicate whether your abstract presents original research. Original research refers to a systematic investigation conducted with the aim of expanding knowledge or understanding, including data analysis.

Please note:

• Clinical trials qualify as original research.
• Reviews, summaries, or literature overviews do not qualify as original research.

Specify whether your abstract reports on a clinical trial.

A clinical trial is defined as a research study in which one or more human participants are prospectively assigned to one or more interventions (including placebo or other controls) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

Indicate whether the research was funded by:

• A government agency
• A pharmaceutical or biotechnology company
• A foundation
• Another source

If funded by a pharmaceutical or biotechnology company, provide a contact person at that company.

All studies involving human subjects must:

• Comply with the policies of the appropriate IRB or equivalent institutional ethics body.
• Conform to the ethical standards set forth in the most recent revision of the Declaration of Helsinki.

If your abstract is accepted, you must provide:

• The name of the approving IRB
• The date of IRB approval

Note: IRB approval must precede the conduct of the research. All accepted abstracts must include a disclosure statement that includes the name and approval date of the IRB.

Your abstract title should objectively describe the study topic without including results or conclusions.

KRF reserves the right to revise titles that imply or state findings or conclusions.

KRF is committed to promoting transparency, scientific rigor, and the highest ethical standards.

All authors must disclose any financial relationships or potential conflicts of interest with for-profit healthcare companies. The first author is responsible for collecting and submitting disclosure information for all co-authors.

If the first author is employed by a company as defined by the CMSS Code for Interactions with Companies, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation.

A Company is defined as "A for-profit entity that develops, produces, markets, or distributes drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions. This definition is not intended to include non-profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients."

The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste from an existing document, or upload a text file of your abstract.

Do not exceed 1200 for the total of your abstract title, body including section titles, and table. One data table is permitted per abstract. Illustrations and figures are not permitted.

KRF recognizes the importance of bringing together researchers to discuss ongoing trials. Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration and discuss correlatives and novel trial designs.

All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a Trials in Progress submission. Since the trials submitted are ongoing and have not reached pre-specified endpoints for analysis, the inclusion of results would be improper and is strictly forbidden.

Authors are required to use standardized keloid terminology whenever possible. For proper terminology and definitions, please refer to the Keloid Research Foundation (KRF) Nomenclature Page .

For all clinical studies and clinical trials, authors are required to provide staging information for study participants according to the KRF Keloid Staging System .

Submission of clinical outcomes without appropriate staging information limits the interpretation and comparability of study results.

When reporting treatment outcomes, authors should use the KRF RECORD (Response Evaluation Criteria in Keloid Disorder) Response Criteria to ensure consistency, reproducibility, and comparability across studies.